PRLD

3.2250.92%
PA

Paul A. Friedman

Independent Chairman of the Board

Dr. Paul A. Friedman, M.D., was Independent Chair of Genesis Therapeutics Inc. since April 2024 until May 2026 and serves as its Independent Director. Dr. Friedman has been Independent Chairman of the Board at Prelude Therapeutics Incorporated and has been its Independent Director since July 2016. He had been Chief Executive Officer of Madrigal Pharmaceuticals, Inc. since July 22, 2016 until September 2023 and served as its Chairman since July 22, 2016 until June 15, 2023. He had been Director at Madrigal Pharmaceuticals, Inc. from July 2016 until June 2026. He served as an Independent Director at Alexion Pharmaceuticals, Incorporated until July 21, 2021. He serves as an Independent Director at Gliknik, Inc. Dr. Friedman served as a Member of Synta Pharmaceuticals Corp.’s Board of Directors from March 2014 until April 2016. Dr. Friedman served as the Chief Executive Officer of Incyte Corporation since November 2001 until January 2014. He was Independent Director of Incyte Corporation since November 2001 until May 26, 2021. From 1994 to 1998, he served as President of Research & Development for the DuPont-Merck Pharmaceutical Company; and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. Dr. Friedman had been Member of Clinical and Scientific Advisory Board at Verastem, Inc. Dr. Friedman was Director of Cerulean Pharma Inc. until January 2017, Verastem, Inc., until April 2017. He served as Director at Navitor Pharmaceuticals, Inc. He has previously served on the Board of Directors of Auxilium Pharmaceuticals Inc., a publicly traded pharmaceutical company and Durata Therapeutics, Inc., a publicly traded pharmaceutical company. Dr. Friedman received his A.B. in Biology from Princeton Universit.

Positions